HIGHLIGHTS
- who: Hao-Ran Zheng from the Nanjing University, China have published the research: The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study, in the Journal: (JOURNAL) of October/31,/2021
- what: This study provided real-world data of anlotinib combined with platinum-etoposide chemotherapy as the first-line treatment for ESSCLC at the first time.
- how: The authors conducted this multicenter retrospective study to investigate the real-world efficacy and safety of anlotinib combined . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.